Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

BR96-doxorubicin immunoconjugate

An antibody-drug conjugate composed of the chimeric monoclonal antibody BR96 chemically linked to the cytotoxic drug doxorubicin. The antibody moiety of BMS-182248-1 binds to Lewis Y, a cell surface antigen expressed on many solid tumor types. Thus, the doxorubicin conjugate is targeted specifically to Lewis Y-expressing tumor cells, where it intercalates with DNA, thereby inhibiting DNA replication and repair, RNA synthesis and protein synthesis. (NCI)

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	BR96-DOX immunoconjugate BR96-doxorubicin BR96-doxorubicin conjugate cBR96-doxorubicin immunoconjugate
Abbreviation:	BR96-DOX
Code name:	BMS-182248-01 SGN-15

BR96-doxorubicin immunoconjugate

Search NCI's Drug Dictionary